Our October summit was generously hosted by Genentech at their South San Francisco headquarters. Special thanks to the team at Genentech and the DHC members who worked to deliver another informative and worthwhile event.
The event wrapped up with an executive fireside chat with Gina Chapman, Vice President and U.S. head of Avastin, Herceptin, and Rituxan, Genentech and Mark Bard, Co-founder, DHC featuring an introspective discussion of the forces at play in pharma today. They celebrated the shift towards a more truly patient-centric environment and explored the ways in which personalized medicine will accelerate that move in the next 5 to 10 years. Below is a transcript of their discussion, edited for length and clarity.
Mark Bard (DHC): What is the biggest insight you’ve gained after 25 years in pharma?
Gina Chapman (Genentech): Over the last ten years, we’ve increasingly recognized the importance of patients as critical to what we do and why we do it. Given both the mix of our portfolio and the small role patients played in decision-making, until relatively recently we weren’t focusing on patients as much as we are today. We’ve also seen our industry increase investments in rare diseases, where people have been suffering for a long time without help. And there are now entire teams focused on managed care, whereas 25 years ago, there might have been just a couple of people in the organization who understood the term “managed care”.
Mark Bard (DHC): When it comes to patient centricity, the resounding answer among pharma is that it’s their strength. Yet our industry ranks low. What trends help us put patients at the center of strategy?
Gina Chapman (Genentech): It’s a complex industry, but the patient is and should be the primary customer. That’s a shift we need to make very quickly. Other stakeholders should be considered partners with us in delivering care. You think of things differently, and potentially make different decisions, when you frame the HCP as a partner and the patient as the customer.